Avacta Reports Progress in Oncology Drug Development; Getech Achieves Revenue Growth and Positive EBITDA
HYDROGEN
Avacta reported £16.9 million in cash as of December 31, 2025, following a £22.5 million equity raise to support its oncology drug development, including the upcoming clinical testing of its FAP-Exd (AVA6103) program. Meanwhile, Getech announced a successful turnaround, projecting a 6% revenue growth to £5 million and an adjusted EBITDA of £500,000 for the same fiscal year, driven by a new sustainable strategy and a 20% cost reduction.
Jan 21, 2026, 6:05 AM
